Mimedx Group, Inc · NASDAQ:MDXG
Mimedx — Investor Presentation (September 2009)
34 slides from Mimedx's investor presentation, Sep 2, 2009
Slide 1: Innovations in Biomaterials
Title Slide-not yet formatted. INNOVATIONS IN BIOMATERIALS
Slide 2: MiMedx Group, Inc. + MiMedx, Inc. + SpineMedica, LLC
iMedx MiMedx Group, Inc. + MiMedx, Inc. + SpineMedica, LLC MiMe GROUP GROUP ou > Z SpineMedica
Slide 3: Forward-Looking Statement
FORWARD-LOOKING STATEMENT This document contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements may be identified by their use of terms or phrases such as "expects," "estimates," "proj
Slide 4: MiMedx Group company overview
MiMedx Group, Inc., (OTCBB: MDXG) is an integrated developer, manufacturer, and marketer of patent protected biomaterial-based products. In 2009, MiMedx Group expects to transition from a pre-revenue, development- focused concern to an operating company focused on sales growth and profitability MiMe
Slide 5: Board of Directors and Management Team
Board of Directors Parker H. "Pete" Petit, Chairman Durable Hydrogel Biomaterials Rebeccah Brown, PhD, COO Based in Atlanta, GA Collagen-Based Biomaterials Thomas Koob, PhD, CSO Based in Tampa, FL Management Team Pete Petit President & CEO Bill Taylor COO (acting) To Be Determined EVP Sales Mike Cul
Slide 6: Board of Directors
BOARD OF DIRECTORS Parker H. (Pete) Petit - Chairman Former Chairman and CEO of Matria Healthcare which was sold to Inverness Medical Innovations in May, 2008 Matria Healthcare was a former subsidiary of Healthdyne, which Mr. Petit founded in 1970 Served as Chairman and CEO of Healthdyne and some of
Slide 7: Consolidated Pro Forma Income Statements
CONSOLIDATED PRO FORMA INCOME STATEMENTS Calendar Year Calendar Year Calendar Year Calendar Year 2009 2010 2011 2012 Net Revenue Net Revenue Net Revenue Net Revenue 105 8,876 21,281 36,000 Cost of Sales Cost of Sales Cost of Sales 1,648 3,272 5,345 7,884 Gross Profit Gross Profit Gross Profit Gross
Slide 8: Consolidated Pro Forma Income Statements by Quarter
CONSOLIDATED PRO FORMA INCOME STATEMENTS 8 2009 Plan 2009 Plan 2009 Plan 2009 Plan 2009 Plan 2010 Plan 2010 Plan 2010 Plan 2010 Plan 2010 Plan 2011 Plan 2011 Plan 2011 Plan 2011 Plan 2011 Plan Q1 Q2 Q3 Q4 YTD Q1 Q2 Q3 Q4 YTD Q1 Q2 Q3 Q4 YTD MiMedx MiMedx MiMedx Revenues Revenues - - - - - - 480 925
Slide 9: Strategic and Tactical Goals
STRATEGIC and TACTICAL GOALS STRATEGIC Create a fast growth and very profitable biomaterials company from the MiMedx Group's diverse intellectual property TACTICAL Exploit intellectual property through internal product development as well as strategic partnerships Develop an independent sales repres
Slide 10: MiMedx Group, Inc. + MiMedx, Inc. + SpineMedica, LLC
iMedx MiMedx Group, Inc. + MiMedx, Inc. + SpineMedica, LLC MiMe GROUP © MiMebx
Slide 11: Collagen Technology for Connective Tissue Repair
Collagen Technology with Exceptional Mechanical Performance and Biocompatibility for Connective Tissue Repair 11 Collagen
Slide 12: MiMedx Collagen: A Biomaterial Scaffold
MiMedx's collagen-based biomaterial products act as platforms or scaffolds on which a patient's tissue grows during the healing process in order to achieve healthy tissue reconstruction without significant scarring. While the patient's own cells are fabricating their own natural structure, MiMedx im
Slide 13: Product Characteristics
Collagen is cross-linked using a proprietary and patented process Although intended only to augment soft tissue during repair, our collagen fibers are stronger human tendons and ligaments Approximately same stiffness as human tendons and ligaments Forms a scaffold when implanted which allows for cel
Slide 14: Product Potential Uses
Orthopedic soft tissue augmentation and repair-tendons and ligaments Repair for shoulder & rotator cuff, hand & elbow, knee, hip Repair for foot and ankle-posterior tibial, peroneal, extensor and lateral tendons General surgery & wound care Diabetic foot ulcers, plantar soft tissue augmentation, ten
Slide 15: Product Opportunities
Orthopedics and Connective Tissue Reconstruction Tendon and ligament augmentation during repair Sutures for tying tissue Tubes for anchoring to bone Wound Repair Patches for wound healing which immediately covers and protects against infection May act as a scaffold for full repair and healing Other
Slide 16: Product Competition
Tendon Protectors TenoGlide(tm) by Integra Life Sciences and TenoMend(tm) by Collagen Matrix: collagen wraps for protection of repaired tendons Tendon Augmentation or Repair Devices OrthAdapt(r) by Synovis/Pegasus: a collagen soft tissue scaffold in the form of a patch for reinforcement of rotator c
Slide 17: Advantages Over the Competition
Potential advantages over TenoGlide and TenoMend: Our products will also supply protection to the repair site Our products will go beyond simple repair protection by augmenting the repair Potential advantages over GraftJacket, OrthAdapt, and FiberWire: Scalability: we can target fiber geometries to
Slide 18: Proprietary Technology
Patent No. 6,565,960-A broad process patent protects the technology Our collagen-fiber cross-linking patent is strong and broad: no competitor has a collagen fiber as strong, stiff, expandable, scalable, biocompatible and biomimetic, from a biological source. All patents relating to specific product
Slide 19: Product Configurations
Cables Knits Tubes Patches PRODUCT CONFIGURATIONS 19
Slide 20: Superior Strength Versus Competitors
Competitors MiMedx SUPERIOR STRENGTH VERSUS COMPETITORS Individual values taken from published & Company literature Tensile Strength (N) 20
Slide 21: Strength Comparison to Native Tissue
Device strength can be tailored to match that of tendons and ligaments Number of fibers per device STRENGTH COMPARISON TO NATIVE TISSUE Data from published & Company literature 21
Slide 22: Stiffness Comparison to Native Tissue
STIFFNESS COMPARISON TO NATIVE TISSUE Data from published & company literature Stiffness mimics that of human tendons and ligaments 22
Slide 23: MiMedx Physician Advisory Board
Chairman James Andrews, MD Alabama Sports Medicine Center; Birmingham, AL The Andrews Institute; Gulf Breeze, FL Members Leon E Paulos, MD The Andrews Institute; Gulf Breeze, Florida Neal Elattrache, MD Kerlan Jobe Orthopedic Center; Los Angeles, CA Timothy Kremchek, MD Beacon Orthopedics; Cincinnat
Slide 24: MiMedx / SpineMedica
MiMedx S SpineMedica.
Slide 25: Durable, Biocompatible Hydrogel Technology
Durable hydrogel products have numerous opportunities with initial product focus in sheet applications Sheets will have broad market opportunities First product to the market is the Paradis Vaso Shield(tm) DURABLE, BIOCOMPATIBLE HYDROGEL TECHNOLOGY 25 The Paradis Vaso Shield(tm) is FDA cleared for u
Slide 26: Product Characteristics
Silicone-like material with properties that can be tailored A durable hydrogel compound made of polyvinyl alcohol Prohibits cellular attachment or in-growth Patented and proprietary manufacturing processes Biocompatible Durable PRODUCT CHARACTERISTICS 26
Slide 27: Product Potential Uses
Orthopedic Spine Repair FDA cleared as a cover for vessel following anterior vertebral surgery Possible cervical and thoracic anterior and full spine posterior vertebral surgery Future Product Uses Cardiovascular and open heart surgery General surgery Hernia repair Plastic and reconstructive surgery
Slide 28: Product Opportunities
Orthopedics Currently FDA cleared as a vessel cover following anterior vertebral surgery Providing a plane of dissection for surgeon accessibility for revision surgery Expedites the surgical process Reduces risk to patient during revision surgery Foot and Ankle Cushion device Wound covering Other Op
Slide 29: Product Competition
Preclude(r) Vessel Guard by W.L. Gore Only direct competitor Similar FDA indication to Vaso Shield Product is opaque Made of ePTFE (expanded-PolyTetraFloroEthylene) Seprafilm(r) by Genzyme FDA indication as an anti-adhesion barrier in open abdominal surgery Sometimes is used off-label for anterior v
Slide 30: Advantages Over the Competition
Potential advantages of Vaso Shield over Preclude Vessel Guard: Translucent Surgeon can see through implant Makes suturing easier Makes implanting faster Makes using safer MRI-clearly visible on MRI, Preclude is not Thickness-easier to handle and does not fold over on itself Thickness-easier to feel
Slide 31: Proprietary Technology
Durable Viscoelastic Polymer Own and Licensed IP for products and manufacturing 6 Issued, 23 pending patents securing technology-US & Foreign Material texture is similar to silicone without associated negative properties, such as silicone wear debris, biocompatibility issues Mimics properties of hum
Slide 32: Vaso Shield
FDA Cleared 510(k) as a vessel cover following anterior vertebral surgery Visible on MRI Sutured into place Vaso Shield being implanted First implant procedure VASO SHIELD 32
Slide 33: Cervical Design Team and SpineMedica Physician Advisory Board
CERVICAL DESIGN TEAM Carl Lauryssen, MD, Chairman Cedars-Sinai Hospital; Los Angeles, CA Darrel Brodke, MD University Health Care; Salt Lake City, UT Daniel Riew, MD Washington University; St. Louis, MO John McClellan, MD Nebraska Spine Center LLP; Omaha, NE Randal Betz, MD, Chairman Shriners Hospit
Slide 34: MiMedx Group, Inc. + MiMedx, Inc. + SpineMedica, LLC
ied MiMedx Group, Inc. + MiMedx, Inc. + SpineMedica, LLC SpineMedica
MiMedx Group — Investor Presentation (September 2009) on 6ix